Pan et al., have shown that gefitinib could selectively inhibit EGFR and decrease DNA-PK activity, thereby enhancing cytotoxicity by cisplatin against NSCLC cells [37]. The gene discussed is PRKDC; the disease is non-small cell lung carcinoma.